Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites

Paolo Angeli,1 Pere Gines,2,3,4,5 Florence Wong,6 Mauro Bernardi,7 Thomas D Boyer,8 Alexander Gerbes,9 Richard Moreau,10,11,12 Rajiv Jalan,13 Shiv K Sarin,14 Salvatore Piano,1 Kevin Moore,15 Samuel S Lee,16 Francois Durand,17,18 Francesco Salerno,19 Paolo Caraceni,7 W Ray Kim,20 Vicente Arroyo,2,3,4 Guadalupe Garcia-Tsao21

INTRODUCTION
Acute renal failure (ARF) is a common complication in patients with decompensated cirrhosis. The traditional diagnostic criteria of renal failure in these patients were proposed in 19961 and have been refined in subsequent years.2 According to these criteria, ARF is defined as an increase

1 Unit of Hepatic Emergencies and Liver Transplantation, Department of Medicine—DIMED, University of Padova, Padova, Italy; 2 Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain; 3 Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 4 Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERBH), Barcelona, Spain; 5 Instituto Reina Sofia d’Investigación en Nefrología (IRSIN), Barcelona, Spain; 6 Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada; 7 Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 8 Department of Medicine, Liver Research Institute, University of Arizona, College of Medicine, Tucson, Arizona, USA; 9 Liver Unit, Klinikum Munich, Ludwig Maximilian University of Munich, Munich, Germany; 10 InsERM UT149, Centre de recherche sur l’inflammation (CRI), Paris, France; 11 UMR S 1149, Université Paris Diderot, Paris, France; 12 DHU UNITY, Service d’hépatologie, Hôpital Beaujon, APHP, Clichy, France; 13 Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, UK; 14 Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India; 15 UCL Institute of Liver and Digestive Health, Royal Free Campus, University College London, London, UK; 16 Liver Unit, University of Calgary, Calgary, Canada; 17 Hepatology and Liver Intensive Care Unit, Hospital Beaujon, Clichy, France; 18 INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon CRBB, Clichy, France; 19 Policlinico IRCCS San Donato, Medicina Interna ed Epato logia, Università di Milano, Milano, Italy; 20 Division of Gastroenterology and Hepatology, Stanford University Medical School, Palo Alto, California, USA; 21 Division of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Correspondence to Professor Paolo Angeli, Department of Medicine (DIMED) and Unit of Hepatic Emergencies and Liver Transplantation, University of Padova, Via Giustinianni 2, Padova 35100, Italy; pangelo@unipd.it

in serum creatinine (sCr) of ≥50% from baseline to a final value ≥1.5 mg/dL (133 μmol/L). However, the threshold value of 1.5 mg/dL (133 μmol/L) sCr to define renal failure in patients with uncompensated cirrhosis has been challenged.3,4 In addition, the timeframe to distinguish acute from chronic renal failure has not been clearly identified, the only exception being type 1 hepatorenal syndrome (HRS). Meanwhile, new definitions for ARF, now termed acute kidney injury (AKI), have been proposed and validated in patients without cirrhosis.5–7 Recently these new criteria were also proposed and applied in the diagnosis of AKI in patients with cirrhosis.8–15 Thus, in December 2012, the International Club of Ascites (ICA) organised a consensus development meeting in Venice, Italy, in order to reach a new definition of AKI in patients with cirrhosis. The discussion among the experts continued thereafter for 2 years, both online and through several meetings, between those experts who had different positions on crucial points on the subject. This paper reports the scientific evidence supporting the final proposal of a new approach to the diagnosis and treatment of this condition, on which the experts agreed.

DIAGNOSTIC CRITERIA OF AKI AND THEIR APPLICATION IN PATIENTS WITH CIRRHOSIS
AKI is defined as an acute significant reduction in the glomerular filtration rate (GFR). sCr remains the most practical biomarker of renal function in patients with ARF (with or without cirrhosis). However, sCr as a biomarker of renal function has many limitations in clinical practice since it is influenced by bodyweight, race, age, and gender. The use of sCr in patients with cirrhosis is also affected by: (1) decreased formation of creatinine from creatine in muscles, secondary to muscle wasting;16 (2) increased renal tubular secretion of creatinine;17 (3) the increased volume of distribution in cirrhosis that may dilute sCr; (4) interference with assays for sCr by elevated bilirubin.18 As a consequence, measurement of sCr in patients with cirrhosis overestimates GFR or kidney function. Therefore, the use of a fixed threshold of sCr at 1.5 mg/dL (133 μmol/L) to define AKI in cirrhosis is problematic, because of two crucial problems. The first is that an sCr value of 1.5 mg/dL (133 μmol/L) often signifies that GFR is markedly decreased (to ~30 mL/min);19 secondly, the fixed threshold does not take into account the dynamic changes in sCr that occur in the preceding days or weeks, which are needed to distinguish between acute and chronic kidney injury. Since the use of a single value of sCr is not sufficient to diagnose AKI, a dynamic definition referring to an acute increase of sCr to ≥50% from baseline to a final value ≥1.5 mg/dL (133 μmol/L) has been used in several clinical studies in patients with cirrhosis (table 1). AKI, as defined by these criteria, was a strong predictor of in-hospital mortality in patients with cirrhosis.20–23 In recent years, diagnostic criteria have been proposed for the diagnosis of ARF in non-cirrhotic patients, now termed AKI. In particular, two separate bodies developed and published two consensus definitions of AKI: the Acute Dialysis Quality Initiative group for the Risk, Injury, Failure, Loss of Renal Function and End-Stage Renal Disease (RIFLE) criteria; and the Acute Kidney Injury Network (AKIN) group for the AKIN criteria (table 1). More recently, a panel of experts has suggested combining part of the AKIN criteria (increase of sCr of 0.3 mg/dL (26.5 μmol/L) within 48 h or by ≥50% from baseline together with a reduction in urine output to <0.5 mL/kg/h for >6 h) with part of the RIFLE criteria (increase of sCr ≥50% within 1 week or a reduction in GFR by ≥25% together with a reduction in urine output to <0.5 mL/kg/h for >6 h), thus leading to the proposal of the Kidney Disease Improving Global Outcome (KDIGO) criteria (table 1). However, the use of a reduction in urine output in patients with cirrhosis and ascites as a diagnostic criterion is a problem, since these patients are frequently oliguric with avid sodium retention and yet may maintain a relatively normal GFR.24 Conversely, these patients may have an increased urine output because of diuretic treatment. Thus, urine collection is often inaccurate in clinical
Table 1: Current diagnostic criteria for acute kidney injury (AKI) in the general population and in patients with cirrhosis

<table>
<thead>
<tr>
<th>Criteria</th>
<th>RIFLE criteria</th>
<th>AKIN criteria</th>
<th>KDIGO criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic criteria</td>
<td>Increase in sCr to ≥1.5 times baseline, within 7 days; or GFR decrease ≥25%; or Urine output &lt;0.5 mL/kg/h for 6 h</td>
<td>Increase in sCr by ≥0.3 mg/dL (133 μmol/L) within 48 h; or Increase in sCr ≥1.5 times baseline within 48 h; or Urine output &lt;0.5 mL/kg/h for 6 h</td>
<td>Increase in sCr by ≥0.3 mg/dL (133 μmol/L) within 48 h; or Increase in sCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or Urine output &lt;0.5 mL/kg/h for 6 h</td>
</tr>
<tr>
<td>Staging</td>
<td>Risk: sCr increase 1.5–1.9 times baseline; or GFR decrease 25–50%; or Urine output &lt;0.5 mL/kg/h for 6 h</td>
<td>Stage 1: sCr increase 1.5–1.9 times baseline; or sCr increase ≥0.3 mg/dL (133 μmol/L); or Urine output &lt;0.5 mL/kg/h for 6 h</td>
<td>Stage 1: sCr increase 1.5–1.9 times baseline; or sCr increase ≥0.3 mg/dL (133 μmol/L); or Urine output &lt;0.5 mL/kg/h for 6–12 h</td>
</tr>
<tr>
<td></td>
<td>Injury: sCr increase 2.0–2.9 times baseline; or GFR decrease 50–75%; or Urine output &lt;0.5 mL/kg/h for 12 h</td>
<td>Stage 2: sCr increase 2.0–2.9 times baseline; or sCr increase ≥0.3 mg/dL (133 μmol/L); or Urine output &lt;0.5 mL/kg/h for 24 h</td>
<td>Stage 2: sCr increase 2.0–2.9 times baseline; or Urine output &lt;0.5 mL/kg/h for ≥12 h</td>
</tr>
<tr>
<td></td>
<td>Failure: sCr increase ≥3.0 times baseline; or GFR decrease ≥75%; or sCr increase ≥4.0 mg/dL (535.6 μmol/L) with an acute increase of at least 0.5 mg/dL (44 μmol/L); or Urine output &lt;0.5 mL/kg/h for ≥24 h; or Anuria for ≥12 h</td>
<td>Stage 3: sCr increase 3.0 times baseline; or sCr increase ≥4.0 mg/dL (535.6 μmol/L) with an acute increase of at least 0.5 mg/dL (44 μmol/L); or Urine output &lt;0.5 mL/kg/h for ≥12 h; or Anuria for ≥12 h</td>
<td>Stage 3: sCr increase 3.0 times baseline; or sCr increase ≥4.0 mg/dL (535.6 μmol/L); or Initiation of renal replacement therapy; or Urine output &lt;0.3 mL/kg/h for ≥24 h; or Anuria for ≥12 h</td>
</tr>
</tbody>
</table>

AKIN, Acute Kidney Injury Network; GFR, glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss, End stage renal disease; sCr, serum creatinine.

However, whether these observations can be extended to patients with cirrhosis is not clear. Several studies have shown that the use of RIFLE criteria for AKI in cirrhosis and the use of continuous renal replacement therapy might be similar to those without AKI. Patients with AKI stage 2 or 3 had higher short-term mortality than those without AKI. Patients with AKI Stage 2 and 3 had a higher rate of mortality than those without AKI, but the difference was not statistically significant. Patients with AKI Stage 2 or 3 had a higher rate of mortality than those without AKI, but the difference was not statistically significant. Patients with AKI Stage 2 or 3 had a higher rate of mortality than those without AKI, but the difference was not statistically significant.

The main challenge in the diagnosis of AKI is determining the appropriate threshold for AKI. The threshold for AKI may vary depending on the setting and the patient population. The threshold for AKI may be different in intensive care units and acute care settings. The threshold for AKI may be different in intensive care units and acute care settings. The threshold for AKI may be different in intensive care units and acute care settings. The threshold for AKI may be different in intensive care units and acute care settings.

Angell et al. Gut 2015;64:469.4

Cite this as: Gut 2015;64:469.4

31 April 2015 Vol 64 No 4

Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is

13 15 Further, the dependent fashion is
be generalised to all hospitalised patients with cirrhosis should be assessed in future studies. In fact, as far as the impact of peak AKI stage 1 on in-hospital mortality, it has recently been observed that in patients who developed AKI as a consequence of a bacterial infection, those with stage 1 AKI and a final sCr ≤1.5 mg/dL (133 μmol/L) had a higher short term mortality compared to those without AKI.11 In addition, regarding regression of AKI stage, it has recently been observed (in non-hospitalised patients) that despite resolution of most AKI episodes in patients with advanced cirrhosis, a gradual and significant increase in sCr and a gradual reduction in mean arterial pressure were observed during follow-up, associated with a significant reduction in mid-term survival compared with non-AKI patients.11 Indeed, the main lesson learnt from the application of AKIN criteria is that even a small increase in sCr should be identified as early as possible for potential early interventions.

WHY DO WE NEED TO CHANGE THE CONVENTIONAL DIAGNOSTIC CRITERIA FOR AKI?

A recent editorial on the topic of AKI in cirrhosis29 asked the question: “Should we change current definition and diagnostic criteria of renal failure in cirrhosis?” Currently, studies on AKI in patients with cirrhosis showed that AKI defined by an absolute increase in sCr ≥0.3 mg/dL (26.5 μmol/l) and/or ≥50% from baseline is associated with a higher probability of the patients being transferred to the intensive care unit, a longer hospital stay, and an increased in-hospital as well as 90-day and mid-term mortality.8–15 On the basis of this evidence, all the experts agreed that it was time to change our current definition of renal failure by introducing a modified version of the KDIGO criteria for the diagnosis of AKI in patients with cirrhosis (table 2). In the new ICA criteria for the diagnosis of AKI, the use of urine output as one of the criteria has been removed since it does not apply to patients with cirrhosis (ie, many patients are oliguric but have preserved kidney function) and it has never been investigated. Further, two other changes to the KDIGO criteria were adopted, namely: (1) a sCr within the last 3 months before admission is considered a baseline value for the diagnosis of AKI when a value within the previous 7 days is not available; and (2) the calculation of the baseline sCr by the reverse application of the Modification of Diet in Renal Disease (MDRD) formula, using an arbitrarily defined normal value of GFR of 75 mL/min/1.73 m², was not included. These two points are specifically discussed in the next section.

DEFINITION OF BASELINE SERUM CREATININE FOR THE DIAGNOSIS OF AKI

The first step in applying the ICA-AKI criteria is to define a baseline sCr. It has been stated that a renal disease process that results in a change in sCr over several weeks cannot be defined as AKI, although it may still represent an important clinical entity.7 Nevertheless, as with any clinical scenario, the timeframe for the definition of AKI is somewhat arbitrary, and it is mainly suitable for the diagnosis of AKI in hospitalised patients using a sCr value on or after admission as baseline (hospital-acquired AKI). However, as in the general population, many patients with cirrhosis can develop AKI before admission to hospital (community-acquired AKI). Indeed, in previous studies where pre-admission values of sCr were used as baseline, the rate of AKI was higher than in those based on sCr on admission as baseline (47% vs 26%).9,10 Thus, the diagnosis of community-acquired AKI on admission is related to two possible scenarios: (1) the patient with an available sCr value before admission; and (2) the patient without an sCr value before admission. The use of pre-admission values of sCr poses a great dilemma: how far back can a baseline value of sCr be retrieved and still be expected to be ‘valid’ for the definition of AKI? In the general population, it is reasonable to assume that sCr will be stable over several months or even years, so that an sCr obtained 6 months or even 1 year previously would reasonably reflect the patient’s premorbid baseline.7–29 In patients with cirrhosis, an application of a more rigorous time frame for the definition of AKI seems even more important. In fact, in these patients, impairment of renal function may progress gradually as they go from a compensated to a decompensated state and then more rapidly as the decompensated state worsens. In addition, it should be considered that almost all patients with cirrhosis and ascites receive diuretics that can transiently impair renal function and, thus, increase sCr.

Furthermore, it is important to emphasise the variability in sCr measurements from laboratory to laboratory or even within the same laboratory due to, for example, fluctuations in serum bilirubin in patients with cirrhosis.30 A sCr obtained <7 days before admission would be the ideal condition to use the ICA-AKI criteria, but this timeframe seems unfeasible in most cases. Thus, taking into account the previous experiences, we conclude that use of the last value of sCr within the last 3 months before admission seems

Table 2 International Club of Ascites (ICA-AKI) new definitions for the diagnosis and management of AKI in patients with cirrhosis

<table>
<thead>
<tr>
<th>Subject</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline sCr</strong></td>
<td>A value of sCr obtained in the previous 3 months, when available, can be used as baseline sCr. In patients with more than one value within the previous 3 months, the value closest to the admission time to the hospital should be used. In patients without a previous sCr value, the sCr on admission should be used as baseline.</td>
</tr>
<tr>
<td><strong>Definition of AKI</strong></td>
<td>Increase in sCr ≥0.3 mg/dL (26.5 μmol/L) within 48 h; or percentage increase sCr ≥50% from baseline which is known, or presumed, to have occurred within the prior 7 days.</td>
</tr>
<tr>
<td><strong>Staging of AKI</strong></td>
<td>Stage 1: increase in sCr ≥0.3 mg/dL (26.5 μmol/L) or an increase in sCr ≥1.5-fold to twofold from baseline. Stage 2: increase in sCr ≥two to threefold from baseline. Stage 3: increase of sCr ≥threefold from baseline or sCr ≥4.0 mg/dL (353.6 μmol/L) with an acute increase ≥0.3 mg/dL (26.5 μmol/L) or initiation of renal replacement therapy.</td>
</tr>
<tr>
<td><strong>Progression of AKI</strong></td>
<td>Progression of AKI to a higher stage and/or need for RRT.</td>
</tr>
<tr>
<td><strong>Response to treatment</strong></td>
<td>No response, Partial response, No regression of AKI, Regression of AKI stage with a reduction of sCr to ≥0.3 mg/dL (26.5 μmol/L) above the baseline value.</td>
</tr>
</tbody>
</table>

AKI, acute kidney injury; RRT, renal replacement therapy; sCr, serum creatinine.
more feasible. In this scenario, a community-acquired AKI may be diagnosed in the case of an increase in sCr ≥50% from the last sCr value (table 2). For patients without an available sCr before hospitalisation, the use of an estimated value of sCr as the baseline, calculated by the reverse application of the MDRD formula using a predetermined value of GFR (75 ml/min), has been suggested for the general population of patients. However, it is well known that the MDRD formula is inaccurate in the estimation of GFR in patients with cirrhosis, particularly in those with ascites. As a result, its reverse application in these patients may only add further biases. Preliminary data from the Padua centre suggest that a diagnosis of AKI based on an estimated value of sCr as the baseline identifies <25% of patients with a measured GFR <60 ml/min on admission (Angeli P et al, unpublished observations). However, among patients without an sCr value before admission, one scenario deserves specific mention, and that is the case of the patient with an sCr ≥1.5 mg/dL (133 μmol/L) at admission. The management of such a patient should be based not only on a formal definition of AKI, but also on clinical judgment. Therefore, in a patient with impairment of renal function and a clearly identifiable precipitating event, it would be reasonable to assume that the renal failure represents AKI. Alternatively, the initial sCr may be used as the baseline value, and if AKI criteria are met subsequently then the patient has AKI. This approach was commonly used previously for the diagnosis of type 1 HRS.

A NEW ALGORITHM FOR THE MANAGEMENT OF AKI IN PATIENTS WITH CIRRHOSIS

According to the new ICA-AKI diagnostic criteria for AKI, we propose a new algorithm for the management of AKI in patients with cirrhosis (figure 1). The algorithm is based on the new staging of AKI.

We recommend that patients with cirrhosis and ascites with initial ICA-AKI stage 1 should be managed as soon as possible with the following measures:

1. Review drug chart: review of all medications (including over-the-counter (OTC) drugs), reduction or withdrawal of diuretic therapy, withdrawal of all potentially nephrotoxic drugs, vasodilators or non-steroidal anti-inflammatory drugs (NSAIDs)
2. Plasma volume expansion in patients with clinically suspected hypovolaemia (with crystalloids or albumin or blood transfusion)
3. Prompt recognition and early treatment of bacterial infections when diagnosed or strongly suspected.

Patients who respond with a return of sCr to a value within 0.3 mg/dL (26.5 μmol/L) of the baseline value should be followed closely (assessment of sCr every 2–4 days during the hospitalisation and checked as outpatients at least every 2–4 weeks during the first 6 months after the discharge) for early identification of potential new episodes of AKI. In those cases where there is progression of the AKI stage, the patients should be treated as patients who present with ICA-AKI stage 2 and 3. This treatment should include the withdrawal of diuretics, if this had not been previously implemented, as well as the expansion of plasma volume with intravenous albumin at the dose of 1 g per kg bodyweight per day for two consecutive days, in order to treat pre-renal AKI and to allow differential diagnosis of AKI (box 1). The maximal dose per day of albumin should not exceed 100 g as previously suggested. Further management of patients who do not respond to diuretic withdrawal and plasma volume expansion will obviously

**Figure 1** Proposed algorithm for the management of acute kidney injury (AKI) according to International Club of Ascites—AKI (ICA-AKI) classification that combines Kidney Disease Improving Global Outcomes (KDIGO) criteria and conventional criteria in patients with cirrhosis and ascites. Most of the experts had concerns about the use of vasoconstrictors in patients with AKI stage 1 and sCr <1.5 mg/dL. For the definition of close follow-up, and/or case-by-case, see the text. *Treatment of spontaneous bacterial peritonitis should include albumin infusion according to current guidelines. #Initial AKI stage is defined as AKI stage at the time of first fulfilment of the AKI criteria. §No global consensus was reached on this point. HRS, hepatorenal syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; sCr, serum creatinine.
Box 1 Diagnostic criteria of hepatorenal syndrome (HRS) type of acute kidney injury (AKI) in patients with cirrhosis

**HRS-AKI**
- Diagnosis of cirrhosis and ascites
- Diagnosis of AKI according to ICA-AKI criteria
- No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g/kg bodyweight
- Absence of shock
- No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast media, etc)
- No macroscopic signs of structural kidney injury*, defined as:
  - absence of proteinuria (≥500 mg/day)
  - absence of microhaematuria (>50 RBCs per high power field)
  - normal findings on renal ultrasonography

*Patients who fulfil these criteria may still have structural damage such as tubular damage. Urine biomarkers will become an important element in making a more accurate differential diagnosis between HRS and acute tubular necrosis.

ICA, International Club of Ascites; NSAIDs, non-steroidal anti-inflammatory drugs; RBCs, red blood cells.

**WHY DO WE NEED TO CHANGE THE DIAGNOSTIC CRITERIA OF HRS IN THE SETTING OF AKI?**

A major critical point in the management of AKI in patients with decompensated cirrhosis is whether the diagnostic criteria of type 1 HRS should be revised in light of the new definitions of AKI. The current criteria include a time interval (2 weeks) over which sCr must double to a value >2.5 mg/dL for the diagnosis of type 1 HRS.1,2 A revision of these criteria is needed because the current definition of type 1 HRS does not allow physicians to initiate potentially effective treatment, specifically vasoconstrictors and albumin, until the sCr increases to ≥2.5 mg/dL. Since it has been observed that in patients with type 1 HRS, a higher sCr at the beginning of treatment leads to a lower probability of response to terlipressin and albumin, the most investigated and effective treatment of type 1 HRS,3,34 it seems prudent not to wait until the sCr increases beyond 2.5 mg/dL before starting the treatment. According to the new proposed algorithm, when AKI is characterised by an initial ICA-AKI stage 2 or 3 or by progression of the initial stage despite general therapeutic measures, patients who meet all other diagnostic criteria of HRS provided by the previous definition5 should receive vasoconstrictors and albumin, irrespective of the final value of sCr. This makes it possible to remove a barrier to the achievement of a pharmacological response that was linked to the rigid sCr cut-off value of >2.5 mg/dL in the definition of type 1 HRS. The potential advantage of the algorithm is that its application may allow earlier treatment of patients with type 1 HRS, leading to a better outcome as compared with the current approach. However, we lack studies where vasoconstrictors were used in the treatment of HRS with lower values of sCr, and caution should be exercised in the use of vasoconstrictors in these patients pending further controlled trials.

Nevertheless, all the experts agreed on the removal of the fixed cut-off value of sCr from the diagnostic criteria of HRS. This is the only change that they wanted to introduce in the current diagnostic criteria for HRS. As a consequence, all the remaining criteria are maintained (box 1). However, these criteria do not rule out the possibility of renal parenchymal damage.33 Thus, all the experts agreed on the potential role of new urinary biomarkers in the differential diagnosis of the different types of AKI in patients with cirrhosis. Several urinary biomarkers of tubular damage, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and liver fatty acid-binding protein (L-FABP), have been discovered in recent years. Preliminary experiences from Europe and the USA showed that the use of NGAL35 and/or the combination of urinary biomarkers (NGAL, KIM-1, IL-18, L-FABP and albuminuria)37 may be useful in the differential diagnosis of AKI in patients with cirrhosis. These findings need to be confirmed in future studies.

The removal of a fixed cut-off value of sCr from the diagnostic criteria of HRS in the setting of AKI has important implications in the management of these patients. Thus, there is a need to change the definition of response to the pharmacologic treatment of HRS. Full response will be defined by return of sCr to a value within 0.3 mg/dL (26.5 μmol/L) of the baseline value. Partial responses will be defined by a regression of at least one AKI stage with a fall in the sCr value to ≥0.3 mg/dL (26.5 μmol/L) above the baseline value. Nevertheless, we should recognise that preliminary data suggest that even a partial decrease of sCr from baseline may be associated with improved short term survival, irrespective of whether or not the patient achieves HRS reversal (sCr <1.5 mg/dL).38 These data suggest that the degree of improvement in sCr may be more relevant than achieving a finite level of renal function.
CONCLUSIONS AND FUTURE PERSPECTIVES

Based on the most recent studies on AKI in patients with cirrhosis and ascites, a new algorithm for the management of AKI in these patients is proposed for clinical practice and for future research. The main innovative aspects of this new algorithm are the following:

- The adoption of the main point derived from the application of the KDIGO criteria in the definition of AKI in patients with cirrhosis, namely, use of dynamic changes of sCr
- A more structured diagnostic process, in order to allow a rational application of the therapeutic resources, avoiding potentially undesirable consequences of overtreatment of AKI as a result of indiscriminant use of KDIGO criteria
- The definitive removal of any cut-off value of sCr from the criteria for diagnosis of HRS in the setting of AKI, but maintaining the remaining previous criteria (box 1).

Several issues remain to be addressed: (1) the impact of the management of AKI according to the new algorithm on the outcome of these patients should be tested in future prospective studies; and (2) the role of the new biomarkers of renal tubular damage in predicting the progression and prognosis of AKI, and in the differential diagnosis of the different types of AKI.

In summary, the results of the latest consensus conference of the ICA introduce a new dynamic definition of AKI in patients with cirrhosis, on which a new treatment algorithm is based, representing a substantial change from the traditional criteria used until now in the definition of AKI and type 1 HRS.

Contributors
Organisation of the meeting: PA. Analysis of data from the literature: PA, PG, FW, MB, TDB, AG, RM, RJ, SKS, SP, KM, MSL, FD, FS, PC, WRK, VA, GG. Drafting and writing the manuscript: PA, PG, FW, MB, SP, GG. Critical revision of data and manuscript revision: PA, PG, FW, MB, TDB, AG, RM, RJ, SKS, SP, KM, MSL, FD, FS, PC, VA, GG.

Funding
PG: Research funding from Sequana Medical, Grifols SA; Consultantancy to Ferring Pharmaceuticals; Competitive Public Grant Funding from: Fonds de Investigación Instituto de Salud CarlosIII (FIS12/0330) and Agencia de Gestión d’Ajuts Universitaris de la Recerca (2014 SGR 708). MB: Consultant to CSL Behring GmbH, Baxter Healthcare SA; speaker to Behring GmbH, Baxter Healthcare SA, PPTA Europe. AG: Consultant to CSL Behring. RJ: Consultant to Ocura Therapeutics Inc, Conatus Pharmaceuticals Inc; Research grant from: Grifols Inc, Gambro AB, Sequana Medical AG, Norgine BV, Ocura Therapeutics Inc (the latter five companies are all involved in research collaboration); Speaker to Grifols Inc; Norgine BV; Inventors of Omithine Phenylacetate licensed by UCL to Ocura Therapeutics; UCL spinout Yraig which will in licence five of the following inventions in which R Jalan is the main inventor: YAAQ001 nanoporous carbons for prevention of gut bacterial translocation, UCL liver dialysis device, DASIMAR biomarker for liver failure, Neutrophil for test: biomarker for predicting infection in decompensated cirrhosis. Urinary toll-like receptor 4: diagnostic test for differential diagnosis of renal dysfunction of cirrhosis. SSL: Consultant to Ikaira and Grifols. PC: Lecturer to Baxter Healthcare SA, Kidron, Grifols. VA: Received grant and research support from Grifols.

Competing interests
None.

Provenance and peer review
Not commissioned; externally peer reviewed.

Editors’ note
This article is being published jointly in Gut and Journal of Hepatology.


To cite

Received 20 November 2014
Revised 4 December 2014
Accepted 11 December 2014
Published Online First 28 January 2015
Gut 2015;64:531–537.
doi:10.1136/gutjnl-2014-308874

REFERENCES
28. Bagshaw SM, Uchino S, Cruz D, et al. A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute...


